Rein Therapeutics, Inc. (RNTX) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
RNTX currently has 85.5M outstanding shares. with minimal authorized share overhang for future dilution. The company has significantly diluted shareholders by 268.71% over the past 2 years, indicating aggressive capital raising.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| May 15, 2026 |
10-Q filing | 85.5M shares outstanding |
86M | 0 |
| Mar 26, 2026 |
10-K filing | 25.4M shares outstanding |
25M | 40M |
| Nov 14, 2025 |
10-Q filing | 26.4M shares outstanding |
26M | 39M |
| Sep 03, 2025 |
S-1 filing: This S-1 filing relates to the offer and sale from time to time of up to 10,000,000 shares of common stock by YA II PN, Ltd., with a commitment from the Selling Stockholder to purchase up to $15,000,000 of shares. |
24M | 42M |
| Aug 14, 2025 |
10-Q filing | 24.2M shares outstanding |
24M | 42M |
| May 16, 2025 |
S-3 filing: Rein Therapeutics, Inc. is offering debt securities, common stock, and preferred stock from time to time in one or more offerings of up to $150,000,000 in aggregate offering price. |
22M | 44M |
| May 15, 2025 |
10-Q filing | 21.9M shares outstanding |
22M | 37M |
| Apr 07, 2025 |
10-K filing | 22.0M shares outstanding |
22M | 37M |
| Nov 14, 2024 |
10-Q filing | 21.7M shares outstanding |
22M | 37M |
| Aug 14, 2024 |
10-Q filing | 19.9M shares outstanding |
20M | 39M |
| May 15, 2024 |
10-Q filing | 21.6M shares outstanding |
22M | 37M |
| Apr 15, 2024 |
10-K filing | 17.0M shares outstanding |
17M | 42M |
| Jan 29, 2024 |
S-3 filing: This S-3 filing relates to the resale of up to 7,060,500 shares of common stock by selling stockholders, including shares issuable upon conversion of Series X Preferred Stock and exercise of warrants. |
4.5M | 54M |
| Oct 13, 2023 |
10-Q filing | 4.5M shares outstanding |
4.5M | 47M |
| Aug 11, 2023 |
10-Q filing | 4.5M shares outstanding |
4.5M | 47M |
| May 08, 2023 |
10-Q filing | 4.5M shares outstanding |
4.5M | 47M |
| Mar 20, 2023 |
10-K filing | 4.5M shares outstanding |
4.5M | 47M |
| Nov 01, 2022 |
10-Q filing | 90.8M shares outstanding |
91M | 0 |
| Aug 15, 2022 |
10-Q filing | 90.8M shares outstanding |
91M | 0 |
| Jun 08, 2022 |
S-3 filing: Aileron Therapeutics, Inc. files an S-3 to offer and sell debt securities, common stock, and preferred stock from time to time in one or more offerings of up to $150,000,000 in aggregate offering price and also common stock up to $16,561,000 through an At-The-Market offering. |
91M | 0 |
| May 05, 2022 |
10-Q filing | 90.8M shares outstanding |
91M | 0 |
| Mar 28, 2022 |
10-K filing | 90.6M shares outstanding |
91M | 0 |
| Nov 12, 2021 |
10-Q filing | 90.6M shares outstanding |
91M | 0 |
| Aug 11, 2021 |
10-Q filing | 90.6M shares outstanding |
91M | 0 |
| May 11, 2021 |
10-Q filing | 90.3M shares outstanding |
90M | 0 |
| Mar 24, 2021 |
10-K filing | 90.2M shares outstanding |
90M | 0 |
| Jan 29, 2021 |
S-3 filing: This prospectus relates to the resale of up to 9,000,000 shares of common stock by the selling stockholders. |
41M | 11M |
| Nov 12, 2020 |
10-Q filing | 40.7M shares outstanding |
41M | 2.3M |
| Oct 05, 2020 |
S-1 filing: This S-1 filing relates to the resale of up to 10,551,899 shares of common stock by Lincoln Park Capital Fund, LLC, under a purchase agreement, with the company potentially receiving up to $14.5 million in gross proceeds for working capital and general corporate purposes. |
39M | 3.7M |
| Aug 11, 2020 |
S-3 filing: This S-3 filing relates to the resale of up to 3,700,000 shares of common stock by selling stockholders; the company will not receive any proceeds from the sale of these shares. |
39M | 3.7M |
| Aug 05, 2020 |
10-Q filing | 39.3M shares outstanding |
39M | 0 |
| May 11, 2020 |
10-Q filing | 29.1M shares outstanding |
29M | 0 |
| Mar 30, 2020 |
10-K filing | 27.8M shares outstanding |
28M | 0 |